KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Cash from Investing Activities (2018 - 2024)

Historic Cash from Investing Activities for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2024 value amounting to -$167000.0.

  • Esperion Therapeutics' Cash from Investing Activities changed N/A to -$167000.0 in Q3 2024 from the same period last year, while for Jun 2025 it was -$167000.0, marking a year-over-year decrease of 1133.33%. This contributed to the annual value of -$317000.0 for FY2024, which is 10074.59% down from last year.
  • Per Esperion Therapeutics' latest filing, its Cash from Investing Activities stood at -$167000.0 for Q3 2024.
  • Esperion Therapeutics' 5-year Cash from Investing Activities high stood at $33.0 million for Q3 2022, and its period low was -$50.5 million during Q4 2021.
  • In the last 5 years, Esperion Therapeutics' Cash from Investing Activities had a median value of $1.1 million in 2020 and averaged $1.5 million.
  • Per our database at Business Quant, Esperion Therapeutics' Cash from Investing Activities tumbled by 34198.05% in 2020 and then soared by 25000.0% in 2023.
  • Esperion Therapeutics' Cash from Investing Activities (Quarter) stood at -$12.7 million in 2020, then crashed by 298.26% to -$50.5 million in 2021, then surged by 76.64% to -$11.8 million in 2022, then surged by 248.38% to $17.5 million in 2023, then tumbled by 100.95% to -$167000.0 in 2024.
  • Its Cash from Investing Activities was -$167000.0 in Q3 2024, compared to -$77000.0 in Q2 2024 and -$73000.0 in Q1 2024.